Abstract
Ribonucleotide reductases (RNRs) supply the 2'-deoxyribonucleotide building blocks for DNA synthesis in mammalian cells and for herpes viruses. The viral-encoded RNRs have unique protein sequences that differ from mammalian enzyme primary structures. Selective inhibition of a viral RNR might provide an approach to new anti-herpes agents with minimal effects on the mammalian host RNRs. This review summarizes efforts to develop anti-herpes agents that selectively target viral-encoded RNRs.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antiviral Agents / pharmacology*
-
Antiviral Agents / therapeutic use
-
Enzyme Inhibitors / pharmacology*
-
Enzyme Inhibitors / therapeutic use
-
Herpes Simplex / drug therapy
-
Herpes Simplex / virology
-
Herpesvirus 1, Human / drug effects*
-
Herpesvirus 1, Human / enzymology
-
Herpesvirus 2, Human / drug effects*
-
Herpesvirus 2, Human / enzymology
-
Humans
-
Ribonucleotide Reductases / antagonists & inhibitors*
-
Ribonucleotide Reductases / chemistry
-
Thiosemicarbazones / chemistry
-
Thiosemicarbazones / pharmacology*
Substances
-
Antiviral Agents
-
Enzyme Inhibitors
-
Thiosemicarbazones
-
Ribonucleotide Reductases